Nancy J. Wysenski's most recent trade in Cytokinetics Inc was a trade of 10,880 Non-Qualified Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 10,880 | 10,880 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 7,333 | 30,610 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 38.56 per share. | 15 Apr 2025 | 162 | 23,277 (0%) | 0% | 38.6 | 6,247 | Common Stock |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 48.93 per share. | 02 Jan 2025 | 127 | 23,115 (0%) | 0% | 48.9 | 6,214 | Common Stock |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 52.60 per share. | 01 Oct 2024 | 118 | 22,988 (0%) | 0% | 52.6 | 6,207 | Common Stock |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 114 | 22,870 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 5,600 | 22,756 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 3,636 | 3,636 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Nancy Wysenski J. | Director | Grant, award, or other acquisition of securities at price $ 84.12 per share. | 02 Jan 2024 | 74 | 17,156 (0%) | 0% | 84.1 | 6,225 | Common Stock |
| Alkermes plc | Nancy J. Wysenski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2023 | 5,957 | 21,786 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Nancy J. Wysenski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2023 | 5,957 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Nancy J. Wysenski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.88 per share. | 07 Jul 2023 | 1,430 | 20,356 (0%) | 0% | 29.9 | 42,728 | Ordinary Shares |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 33.36 per share. | 03 Jul 2023 | 187 | 16,858 (0%) | 0% | 33.4 | 6,238 | Common Stock |
| Alkermes plc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 12,732 | 12,732 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 5,985 | 5,985 | - | - | Restricted Stock Unit Award | |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 10,000 | 10,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 5,000 | 16,671 (0%) | 0% | 0 | Common Stock | |
| Alkermes plc | Nancy J. Wysenski | Director | Sale of securities on an exchange or to another person at price $ 31.24 per share. | 09 May 2023 | 41,250 | 15,829 (0%) | 0% | 31.2 | 1,288,786 | Ordinary Shares |
| Alkermes plc | Nancy J. Wysenski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.13 per share. | 09 May 2023 | 35,000 | 50,829 (0%) | 0% | 31.1 | 1,089,550 | Ordinary Shares |
| Alkermes plc | Nancy J. Wysenski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2023 | 35,000 | 0 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy J. Wysenski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.13 per share. | 09 May 2023 | 6,250 | 57,079 (0%) | 0% | 31.1 | 194,563 | Ordinary Shares |
| Alkermes plc | Nancy J. Wysenski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2023 | 6,250 | 0 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 37.71 per share. | 03 Apr 2023 | 149 | 11,671 (0%) | 0% | 37.7 | 5,619 | Common Stock |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 44.35 per share. | 03 Jan 2023 | 126 | 11,522 (0%) | 0% | 44.3 | 5,588 | Common Stock |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 51.11 per share. | 03 Oct 2022 | 110 | 11,396 (0%) | 0% | 51.1 | 5,622 | Common Stock |
| Alkermes plc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 11,554 | 11,554 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 5,957 | 5,957 | - | - | Restricted Stock Unit Award | |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 41.00 per share. | 01 Jul 2022 | 137 | 11,286 (0%) | 0% | 41 | 5,617 | Common Stock |
| Alkermes plc | Nancy J. Wysenski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2022 | 7,585 | 16,524 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Nancy J. Wysenski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2022 | 7,585 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Nancy J. Wysenski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.19 per share. | 14 Jun 2022 | 695 | 15,829 (0%) | 0% | 27.2 | 18,897 | Ordinary Shares |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 38.38 per share. | 01 Apr 2022 | 146 | 6,149 (0%) | 0% | 38.4 | 5,603 | Common Stock |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 46.00 per share. | 03 Jan 2022 | 122 | 6,003 (0%) | 0% | 46 | 5,612 | Common Stock |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 36.74 per share. | 01 Oct 2021 | 153 | 5,881 (0%) | 0% | 36.7 | 5,621 | Common Stock |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 19.77 per share. | 07 Jul 2021 | 31 | 5,728 (0%) | 0% | 19.8 | 613 | Common Stock |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 20.98 per share. | 01 Jul 2021 | 238 | 5,697 (0%) | 0% | 21.0 | 4,993 | Common Stock |
| Alkermes plc | Nancy J. Wysenski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2021 | 6,104 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Nancy J. Wysenski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2021 | 6,104 | 6,104 (0%) | 0% | 0 | Ordinary Shares | |
| Alkermes plc | Nancy J. Wysenski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.92 per share. | 20 May 2021 | 1,404 | 4,700 (0%) | 0% | 21.9 | 30,776 | Ordinary Shares |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 10,000 | 10,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 5,000 | 5,459 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 24.44 per share. | 01 Apr 2021 | 204 | 459 (0%) | 0% | 24.4 | 4,986 | Common Stock |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 19.56 per share. | 04 Jan 2021 | 255 | 255 (0%) | 0% | 19.6 | 4,988 | Common Stock |
| Alkermes plc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2020 | 11,509 | 11,509 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2020 | 5,578 | 5,578 | - | - | Restricted Stock Unit Award | |
| Cytokinetics Inc | Nancy J. Wysenski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 35,000 | 35,000 | - | - | Non-Qualified Stock Option (right to buy) |